Europe - EPA:IPH - FR0010331421 - Common Stock
The current stock price of IPH.PA is 1.58 EUR. In the past month the price decreased by -21.39%. In the past year, price decreased by -19.88%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.12 | 334.23B | ||
AMG.DE | AMGEN INC | 13.04 | 129.50B | ||
GIS.DE | GILEAD SCIENCES INC | 14.74 | 119.81B | ||
1VRTX.MI | VERTEX PHARMACEUTICALS INC | 23.36 | 85.81B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 22.91 | 84.19B | ||
1AE.DE | ARGENX SE | 85.58 | 38.29B | ||
ARGX.BR | ARGENX SE | 85.53 | 38.26B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 19.75B | ||
1BIIB.MI | BIOGEN INC | 9.34 | 18.55B | ||
IDP.DE | BIOGEN INC | 8.96 | 17.79B | ||
1EXEL.MI | EXELIXIS INC | 18.85 | 8.93B | ||
0QF.DE | MODERNA INC | N/A | 8.33B |
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
INNATE PHARMA SA
117 avenue de Luminy, Bp 30191
Marseille PACA FR
Employees: 181
Phone: 33430303030
The current stock price of IPH.PA is 1.58 EUR. The price decreased by -5.16% in the last trading session.
The exchange symbol of INNATE PHARMA SA is IPH and it is listed on the Euronext Paris - Matif exchange.
IPH.PA stock is listed on the Euronext Paris - Matif exchange.
8 analysts have analysed IPH.PA and the average price target is 5.64 EUR. This implies a price increase of 257% is expected in the next year compared to the current price of 1.58. Check the INNATE PHARMA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INNATE PHARMA SA (IPH.PA) has a market capitalization of 145.62M EUR. This makes IPH.PA a Micro Cap stock.
INNATE PHARMA SA (IPH.PA) currently has 181 employees.
INNATE PHARMA SA (IPH.PA) has a support level at 1.53 and a resistance level at 1.77. Check the full technical report for a detailed analysis of IPH.PA support and resistance levels.
The Revenue of INNATE PHARMA SA (IPH.PA) is expected to grow by 172.13% in the next year. Check the estimates tab for more information on the IPH.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IPH.PA does not pay a dividend.
INNATE PHARMA SA (IPH.PA) will report earnings on 2025-09-17, before the market open.
INNATE PHARMA SA (IPH.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
ChartMill assigns a technical rating of 1 / 10 to IPH.PA. When comparing the yearly performance of all stocks, IPH.PA is a bad performer in the overall market: 88.87% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IPH.PA. IPH.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months IPH.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -549.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -44.54% | ||
ROE | -560.01% | ||
Debt/Equity | 8.02 |
8 analysts have analysed IPH.PA and the average price target is 5.64 EUR. This implies a price increase of 257% is expected in the next year compared to the current price of 1.58.
For the next year, analysts expect an EPS growth of 189.51% and a revenue growth 172.13% for IPH.PA